Curis (NASDAQ: CRIS) and Cleveland BioLabs (NASDAQ:CBLI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.


This table compares Curis and Cleveland BioLabs’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Curis -836.18% -236.43% -88.44%
Cleveland BioLabs -253.09% -61.18% -49.90%

Institutional and Insider Ownership

44.7% of Curis shares are held by institutional investors. Comparatively, 4.6% of Cleveland BioLabs shares are held by institutional investors. 4.1% of Curis shares are held by company insiders. Comparatively, 2.4% of Cleveland BioLabs shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Curis and Cleveland BioLabs’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Curis $8.31 million 27.70 -$48.51 million ($0.50) -3.20
Cleveland BioLabs $2.91 million 12.36 -$5.71 million ($0.66) -4.83

Cleveland BioLabs has higher revenue, but lower earnings than Curis. Cleveland BioLabs is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Curis has a beta of 1.87, suggesting that its share price is 87% more volatile than the S&P 500. Comparatively, Cleveland BioLabs has a beta of 0.06, suggesting that its share price is 94% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for Curis and Cleveland BioLabs, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Curis 0 0 2 0 3.00
Cleveland BioLabs 0 0 0 0 N/A

Curis presently has a consensus target price of $6.00, suggesting a potential upside of 275.00%. Given Curis’ higher probable upside, research analysts plainly believe Curis is more favorable than Cleveland BioLabs.


Curis beats Cleveland BioLabs on 8 of the 12 factors compared between the two stocks.

Curis Company Profile

Curis, Inc. is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target programmed death ligand-1 (PDL1) and V-domain Ig suppressor of T-cell activation (VISTA) immune checkpoint proteins, both of which independently function as negative regulators of immune activation. CA-4948 is an oral small molecule drug candidate that is designed to inhibit the Interleukin-1 receptor-associated kinase 4 (IRAK4) kinase, which is a transducer of toll-like receptor or certain interleukin receptor signaling pathways.

Cleveland BioLabs Company Profile

Cleveland BioLabs, Inc. (CBLI) is a biopharmaceutical company. The Company is engaged in developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is Entolimod, an immuno-stimulatory agent, which it is developing as a radiation countermeasure and an immunotherapy for oncology and other indications. Its other products include CBLB612, Mobilan and CBL0137. CBLB612 is a compound based upon a natural activator of another tissue-specific component of the innate immune system, the toll-like receptor 2 (TLR2)/ toll-like receptor 6 (TLR6) heterodimeric receptor. Mobilan is a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. CBL0137 is a small molecule with a multi-targeted mechanism of action that may be useful for the treatment of various types of cancer.

Receive News & Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related companies with's FREE daily email newsletter.